SENSE registry for status epilepticus. (29th August 2018)

• Record Type: Journal Article
• Authors: Kellinghaus, Christoph; Rossetti, Andrea O.; Trinka, Eugen; Lang, Nicolas; Unterberger, Iris; Rüegg, Stephan; Tilz, Christian; Uzelac, Zeljko; Rosenow, Felix
• Is Part Of: Epilepsia. Volume 59(2018)Supplement 2
• Page Start: 150
• Page End: 154
• Publication Date: 2018-08-29
• Subjects: registry -- status epilepticus -- therapy; Epilepsy -- Periodicals; 616.853
• DOI: 10.1111/epi.14495
• Languages: English
• ISSNs: 0013-9580

Abstract

Summary: Evidence is scarce regarding the treatment of status epilepticus (SE). Only a few large randomized controlled trials have been published. Therefore, we set up a multicenter registry to prospectively document treatment practice in several different large hospitals in German‐speaking countries. Over a period of more than 4 years, we were able to document 1179 episodes of 1049 patients who were treated for SE in 1 of the 8 participating centers in Germany, Austria, and Switzerland. Median age was 70 years. The most frequent etiology was remote (32%), followed by acute (31%), or a mixture of acute and remote factors (10%). Semiology was generalized convulsive in 44%, focal motor in 27%, and nonconvulsive in 30%. Only a few patients did not have relevant comorbidities. Median latency between SE onset and first treatment was 1 hour (median). Three hundred ninety‐three (32%) of the patients were treated within 30 minutes after onset. The first treatment step consisted of benzodiazepines in more than 80%, and in levetiracetam in 15%. Five hundred eleven patients (49%) were refractory (defined as ongoing SE after application of benzodiazepine and 1 intravenous anticonvulsant). Further analysis of these registry data may be important for hypothesis generation and trial design for treatment of status epilepticus.